Suite 3101, 31/F., Skyline Tower 39 Wang Kwong Road Kowloon Bay Kowloon Hong Kong COMPANY SECRETARY Ernst & Young Certified Public Accountants Registered Public Interest Entity Auditor PRINCIPAL BANKERS HEAD OFFICE AND PRINCIPAL PLACE OF BUSINESS IN HONG KONG 核數師 禮德齊伯禮律師行有限法律責任合夥 何耀棣律師事務所 蘇利文 • 克倫威爾律師事務所（香港） 有限法律責任合夥 註冊辦事處 4 WAI YUEN TONG MEDICINE HOLDINGS LIMITED 位元堂藥業控股有限公司 MUFG Fund Services (Bermuda) Limited 4th floor North Cedar House 41 Cedar Avenue Hamilton HM 12 Bermuda (to be ceased on 1 January 20 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 佈 全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 WAI YUEN TONG MEDICINE HOLDINGS LIMITED （位 元 堂 藥 業 控 股 有 限 公 司*） （於 百 慕 達 註 冊 成 立 之 有 限 公 司） （股 份 代 號：897） 截至二零二四年九月三十日止六個月之中期業績公佈 | --- | --- | --- | --- | |---------------------------------------------|-----------------------------------------------------|--------------------------------------|-----------------| | | | | | | 中期財務摘要 百萬港元 | 截至九月三十日止六個月 二零二四年 （未 經 審 核） | 二零二三年 （ ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責， 對其準確性或完整性亦不發表聲明，並明確表示，概不就因本公佈全部或任何部分 內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 WAI YUEN TONG MEDICINE HOLDINGS LIMITED （位元堂藥業控股有限 公 司 *） （於百慕達註冊成立之有限公司） （股份代號：897） 截至二零二四年三月三十一日止年度之 全年業績公佈 | --- | --- | --- | --- | |-------------------------------------------|----------------------------------|----------------------------------|----------| | | | | | | 年度財務摘要 | | | | | 百萬港元 | 二零二四年 財政年度 | 二零二三年 財政年度 （已重列） | 按年變動 | | 收益 | 783.9 | 723.6 | 8.3% | | 毛利 | 394.8 | 342.4 | 15.3% | | 年度溢利 | 4 ...

智通财经APP数据显示，截止3月11日收盘，有78只股票创52周新高，其中位元堂(00897)、乐思集团(02540)、博雅互动(00434)创高率位于前3位，分别为198.85%、65.00%、30.64%。另外有54只股票创52周新低，其中中国供应链产业(03708)、呷哺呷哺(00520)、朸濬国际(01355)创低率位于前三位，分别为-41.86%、-13.45%、-10.71%。 52周新高排行 股票名称 收盘价 最高价 创高率 位元堂(00897) 0.226 0.260 198.85% 乐思集团(02540) 2.500 2.640 65.00% 博雅互动(00434) 2.260 2.260 30.64% 光尚文化控股(08082) 0.041 0.042 13.51% 中电华大科技(00085) 1.790 1.840 10.84% 长久股份(06959) 24.500 24.450 10.63% 怡俊集团控股(02442) 1.960 2.360 9.77% TS WONDERS(01767) 0.220 0.220 8.91% 华营建筑(0158 ...

Revenue and Profit Performance - Revenue for the six months ended 30 September 2023 increased to HK$678,804,000, up from HK$606,127,000 in the same period last year, representing a growth of approximately 12%[18] - Gross profit for the period was HK$324,027,000, compared to HK$268,189,000 in the previous year, reflecting a 20.8% increase[18] - Profit before tax for the six months ended 30 September 2023 was HK$38,429,000, a significant improvement from a loss of HK$19,023,000 in the same period last year[18] - Profit attributable to owners of the parent was HK$3.549 million, a turnaround from a loss of HK$53.385 million in the previous year[25] - Basic and diluted earnings per share attributable to ordinary equity holders of the parent were HK0.30 cents, compared to a loss of HK4.35 cents in the same period last year[26] - Revenue for the period reached 2,097,109 units[156] - Profit for the period was 3,549 units[170] Share Repurchase and Issuance - The company repurchased 33,540,000 shares at a total cost of HK$14,727,600 during July 2023, with the highest purchase price per share at HK$0.45 and the lowest at HK$0.425[10] - The total number of shares in issue as of 30 September 2023 was 1,171,102,888[10] - Rich Time, WOE, and Wang On each hold 810,322,940 shares, representing 69.19% of the company's shares[34] - Mr. Tang holds a 50.67% interest in Wang On, which indirectly owns Rich Time and WOE, both holding 810,322,940 shares in the company[36] - Mr. Tang Ching Ho holds 7,320,095,747 shares in CAP, representing approximately 73.54% of CAP's total issued share capital[87] - Mr. Tang Ching Ho is also interested in 810,322,940 shares of the Company held by Rich Time Strategy Limited, with an approximate 50.67% interest[88] Share Option Schemes - The 2013 Share Option Scheme expired on 21 August 2023, and a new 2023 Share Option Scheme was adopted on 22 August 2023, effective for 10 years[40] - The 2023 Share Option Scheme allows the company to grant options to employees, directors, and associates as incentives, with a maximum issuance limit of 10% of the company's issued shares[40] - Any grant of options resulting in shares issued or to be issued exceeding 1% of the company's total shares within a 12-month period requires separate shareholder approval, with the participant and close associates abstaining from voting[42] - Share options granted to directors, chief executives, or substantial shareholders must be approved by independent non-executive directors (INEDs), excluding any INED who is the grantee[42] - Grants to substantial shareholders or INEDs resulting in shares exceeding 0.1% of the company's total shares within 12 months require shareholder approval via a poll, with the grantee and associates abstaining from voting[42] - The exercise period for options is determined by the Board but must not exceed 10 years from the grant date[42] - The minimum holding period before options can be exercised is generally not less than 12 months, with a vesting period that may be shortened under certain circumstances to encourage exceptional performance[42] - The 2023 Share Option Scheme is valid for 10 years starting from August 22, 2023, with no further options to be granted after this period, though existing options remain exercisable[42] - The exercise price for options must not be less than the highest of: (i) the closing price on the grant date, (ii) the average closing price for the 5 business days preceding the grant date, or (iii) the nominal value of the company's shares[42] - No share options were granted, exercised, cancelled, or lapsed under the 2013 and 2023 Schemes during the period, with 117,110,288 share options available for grant as of 30 September 2023[45] - The CAP 2022 Scheme, effective from 26 August 2022, allows the CAP Board to grant share options to eligible participants, with a validity period of 10 years until 25 August 2032[45] - The number of share options granted to any CAP Participant in any 12-month period cannot exceed 1% of the issued CAP Shares without prior shareholder approval[48] - Share options granted to substantial shareholders or independent non-executive directors exceeding 0.1% of issued CAP Shares and HK$5,000,000 in value require prior shareholder approval[48] - The CAP Board may refresh the share option limit to 10% of the total issued CAP Shares, subject to shareholder approval, with a cap of 30% for all outstanding options[49] - As of 30 September 2023, 50,000,000 share options were outstanding for CAP Director Leung Sui Wah, Raymond, with an exercise price of HK$0.118 per share[53] - Other employees had 126,000,000 share options outstanding as of 30 September 2023, down from 161,000,000 due to 35,000,000 lapsed options[53] - The total outstanding share options under the CAP 2012 Scheme decreased from 211,000,000 to 176,000,000 during the period, primarily due to lapsed options[53] - 35,000,000 share options lapsed under the CAP 2012 Scheme, leaving 176,000,000 shares available for issue, representing approximately 1.77% of the existing issued share capital of CAP[56] - No share options were granted, exercised, canceled, or lapsed under the CAP 2022 Scheme, with 995,306,782 share options remaining available for grant as of 30 September 2023[56] Asset and Liability Changes - Total non-current assets decreased to HK$4.057 billion from HK$4.311 billion as of 31 March 2023[27] - Total current assets decreased to HK$2.526 billion from HK$2.702 billion as of 31 March 2023[27] - Net current assets were HK$910.085 million, down from HK$1.045 billion as of 31 March 2023[27] - Trade receivables decreased to HK$66.566 million from HK$68.028 million as of 31 March 2023[27] - Cash and cash equivalents decreased to HK$456 million from HK$525.869 million as of 31 March 2023[27] - Trade payables increased to HK$125.164 million from HK$79.489 million as of 31 March 2023[27] - Other payables and accruals decreased to HK$640.713 million from HK$690.388 million as of 31 March 2023[27] - Total assets less current liabilities decreased from HK$5,356,627,000 to HK$4,968,002,000 as of 30 September 2023[62] - Non-current liabilities decreased from HK$1,668,243,000 to HK$1,482,266,000, primarily due to reductions in unsecured notes and interest-bearing bank borrowings[62] - Net assets decreased from HK$3,688,384,000 to HK$3,485,736,000, with equity attributable to owners of the parent declining from HK$2,349,191,000 to HK$2,225,827,000[62] - Total assets amounted to 2,349,191 units[166] Comprehensive Loss and Other Financial Metrics - Total comprehensive loss for the period was HK$189.922 million, compared to HK$420.356 million in the same period last year, showing a significant improvement[22][25] - Net loss for the period was (27,150) units[157] - Other comprehensive loss for the period was (10,076) units[185] - Changes in fair value resulted in a loss of (23,420) units[186] - Reversal of impairment losses on financial assets was (13,344) units[191] - Reclassification adjustment for gains/losses included in profit or loss was (93) units[200] Corporate Governance - The Company deviated from code provision C.2.1 of the Corporate Governance Code, with Mr. Tang Ching Ho serving as both chairman and managing director[59] - The Company maintains a high standard of corporate governance, emphasizing transparency, accountability, integrity, and independence[60] - The Board comprises three executive Directors and four independent non-executive Directors, ensuring a balance of skills and experience for the Group's development[59]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部分內容而產生或 因倚賴該等內容而引致之任何損失承擔任何責任。 WAI YUEN TONG MEDICINE HOLDINGS LIMITED （位 元 堂 藥 業 控 股 有 限公 司 *） （於百慕達註冊成立之有限公司） （股份代號：897） 截至二零二三年九月三十日止六個月之中期業績公佈 中期財務摘要 截至九月三十日止六個月 二零二三年 二零二二年 變動 百萬港元 （未經審核） （未經審核） 收益 678.8 606.1 12.0% 毛利 324.0 268.2 20.8% 母公司擁有人應佔溢利╱（虧損） 3.5 (53.4) 106.6% 每股盈利╱（虧損）（港仙） — 基本及攤薄 0.30 (4.35) 4.65 於 於 二零二三年 二零二三年 ...

*According to Ipsos’ market survey on consumers of Chinese health supplement products conducted in April 2023 *根據Ipsos 益普索2023年4月中式保健品消費者市場調查結果 Contents 目錄 Independent Auditor’s Report Corporate Information 84 2 獨立核數師報告 公司資料 Consolidated Statement of Awards 5 獎項 92 Profit or Loss and Other Comprehensive Income 綜合損益及其他全面收益表 Chairman’s Statement 6 主席報告 95 Consolidated Statement of Financial Position 綜合財務狀況表 Management Discussion and Analysis 12 管理層討論及分析 97 Consolidated Statement of Changes in Equity 綜合權益變動表 B ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負 責，對其準確性或完整性亦不發表聲明，並明確表示，概不就因本公佈全部或任 何部分內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 WAI YUEN TONG MEDICINE HOLDINGS LIMITED ( 位 元 堂 藥 業 控 股 有 限 公 司 *) （於百慕達註冊成立之有限公司） （股份代號：897） 截至二零二三年三月三十一日止年度之 全年業績公佈 年度財務摘要 百萬港元 二零二三年 二零二二年 財政年度 財政年度 按年變動 收益 1,286.4 1,391.4 (7.5)% 毛利 611.8 570.4 7.3% 母公司擁有人應佔虧損 (20.5) (108.9) 81.2% 每股虧損（港仙） – 基本及攤薄 (1.69) (8.84) 7.15 於二零二三年 於二零二二年 ...

INTERIM REPORT 中期報告 Stock Code 股份代號: 897 YUEN TOI 用心造藥 傳承自年 Wai Yuen Tong Medicine Holdings Limited 位元堂藥業控股有限公司 Incorporated in Bermuda with Imited Iability 於百慕達註冊成立之有限公司 Contents 目錄 Corporate Information 公司資料 2 Interim Dividend 中期股息 4 Management Discussion and Analysis 管理層討論及分析 4 Disclosure of Interests 權益披露 23 Share Option Scheme 購股權計劃 28 Corporate Governance and Other Information 企業管治及其他資料 31 34 Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income 簡明綜合損益及其他全面收益表 37 Condensed ...

调年 Wai Yuen Tong Medicine Holdings Limited 位 元 堂 藥 業 控 股 有 限 公 司 2022 Annual Report I 年報 Incorporated in Bermuda with limited liability 於百慕達註冊成立之有限公司 Stock Code 股份代號: 897 用心造藥 傳承百年 Contents 目錄 2 Corporate Information 公司資料 4 Awards 獎 項 6 Chairman's Statement 主席報告 14 Management Discussion and Analysis 管理層討論及分析 34 Board of Directors and Senior Management 董事會及高級管理層 38 Corporate Governance Report 企業管治報告 57 Report of the Directors 董事會報告 76 Independent Auditor's Report 獨立核數師報告 84 Consolidated Statement of Profit o ...